Mereo BioPharma treatment granted PRIME designation by EMA

By

Sharecast News | 13 Nov, 2017

Updated : 14:45

20:48 22/03/17

  • 3.46
  • 0.61%0.02
  • Max: 3.55
  • Min: 3.46
  • Volume: 0
  • MM 200 : n/a

Clinical stage biopharmaceutical company Mereo BioPharma Group announced on Monday that the the European Medicines Agency has granted BPS-804 ‘PRIority MEdicines’ (PRIME) designation for the treatment of osteogenesis imperfecta (OI), or ‘brittle bone disease’.

Last news

London close: Stocks mixed ahead of UK inflation data
Most Microlise customer systems back up after cybersecurity incident
Broker tips: XPS Pensions, John Wood Group
Director dealings: McBride chairman raises stake
US open: Stocks mixed following last week's heavy losses